The neuroimmunology of Multiple sclerosis

Advances in Neuroimmunology

Volumn 6, Issue 2, 1996, Pages 143-154

  Coyle, P K ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

demyelinating disease; EAE; Multiple sclerosis; neuroimmunology

Indexed keywords

CYTOKINE; IMMUNOMODULATING AGENT; VACCINE;

ENDOTHELIUM CELL; GENETIC PREDISPOSITION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; REVIEW;

EID: 0029745121     PISSN: 09605428     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-5428(96)00013-7     Document Type: Article

References (83)

1. Anderson, D. W., Ellenberg, J. H., Leventhal, C. M., Reingold, S. C., Rodriguez, M. and Silberberg, D. H. (1992). Revised estimate of the prevalence of Multiple sclerosis in the United States. Ann. Neurol. 31: 333-336.
2. Antel, J. P., Williams, K., Blain, M., McRea, E. and McLaurin, J. (1994). Oligodendrocyte lysis by CD4+ T cells independent of tumor necrosis factor. Ann. Neurol. 35:341-348.
3. Archelos, J. J., Jung, S., Maurer, M., Schmied, M., Lassman, H., Tamatani, T., Miyasaka, M., Toyka, K. V. and Hartung, H.-P. (1993). Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. Ann. Neurol. 34:145-154.
4. Battistini, L., Selmaj, K., Kowal, C., Ohmen, J., Modlin, R. L., Raine, C. S. and Brosnan, C. F. (1995). Multiple sclerosis: limited diversity of the Vδ2-Jδ3 T-cell receptor in chronic active lesions. Ann. Neurol. 37:198-203.
5. Challoner, P. B., Smith, K. T., Parker, J. D., Macleod, D. L., Coulter, S. N., Rose, T. M., Schultz, E. R., Bennett, J. L., Garber, R. L., Chang, M., Schad, P. A., Stewart, P. M., Nowinski, R. C., Brown, J. P. and Burmer, G. C. (1995). Plaque-associated expression of human herpesvirus 6 in Multiple sclerosis. Proc. Natl Acad. Sci. 92:7440-7444.
6. Cohen, S., Tyrell, D. A. J. and Smith, A. P. (1991). Psychological stress and susceptibility to the common cold. N. Engl. J. Med. 325:606-612.
7. Constantinescu, C. S. and Cohen, J. A. (1994). Regulatory-cytokine therapy for autoimmune diseases: implications for Multiple sclerosis. Clin. Issues 1:6-9.
8. De Stefano, N., Matthews, P. M., Antel, J. P., Preul, M., Francis, G. and Arnold, D. L. (1995). Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann. Neurol. 38:901-909.
9. Dobbs, C. M., Vasquez, M., Glaser, R. and Sheridan, J. F. (1993). Mechanisms of stress-induced modulation of viral pathogenesis and immunity. J. Neuroimmunol. 48:151-160.
10. Dore-Duffy, P., Newman, W., Balabanov, R., Lisak, R. P., Mainolfi, E., Rothlein, R. and Peterson, M. (1995). Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with Multiple sclerosis: correlation with clinical activity. Ann. Neurol. 37:55-62.
11. Durelli, L., Bongioanni, M. R., Cavallo, R., Ferrero, B., Ferri, R., Ferrio, M. F., Bradac, G. B., Riva, A., Vu, S., Geuna, M., Bergamini, L. and Bergamasco, B. (1994). Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting Multiple sclerosis. Neurology 44:406-413.
12. Ebers, G. C., Sadovnick, A. D., Risch, N. J. and the Canadian Collaborative Study Group (1995). A genetic basis for familial aggregation in Multiple sclerosis. Nature 377:150-151.
13. Filippi, M., Horsfield, M. A., Campi, A., Mammi, S., Pereira, C. and Comi, G. (1995a). Resolution-dependent estimates of lesion volumes in magnetic resonance imaging studies of the brain in Multiple sclerosis. Ann. Neurol. 38:749-754.
14. 2-weighted brain MRI activity in Multiple sclerosis: a follow-up study. Neurology 45:255-260.
15. Foley, F. W., Traugott, U., LaRocca, N. G., Smith, C. R., Perlman, K. R., Caruso, L. S. and Scheinberg, L. C. (1992). A prospective study of depression and immune dysregulation in Multiple sclerosis. Arch. Neurol. 49:238-244.
16. Francis, G. S., Evans, A. C. and Arnold, D. L. (1995). Neuroimaging in Multiple sclerosis. Neurol. Clinics 13:147-171.
17. Franklin, G. M., Nelson, L. M., Heaton, R. K., Burk, J. S. and Thompson, D. S. (1988). Stress and its relationship to acute exacerbations in Multiple sclerosis. J. Neurol. Rehab. 2:7-11.
18. Fricchione, G. L. and Stefano, G. B. (1994). The stress response and autoimmunoregulation. Adv. Neuroimmunol. 4:13-27.
19. Goverman, J., Woods, A., Larson, L., Weiner, L. P., Hood, L. and Zaller, D. M (1993). Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 72:551-560.
20. Grant, I., Brown, G. M., Harris, T., McDonald, W. I., Patterson, T. and Trimble, M. R. (1989). Severely threatening events and marked life difficulties preceding onset or exacerbation of Multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 52:8-13.
21. Hartung, H. P. (1993). Immune-mediated demyelination. Ann. Neurol. 33:563-567.
22. Hartung, H. P., Reiners, K., Archelos, J. J., Michels, M., Seeldrayers, P., Heidenreich, F., Plughaupt, K. W. and Toyka, K. (1995). Circulating adhesion molecules and tumor necrosis factor receptor in Multiple sclerosis: correlation with magnetic resonance imaging. Ann. Neurol. 38:186-193.
23. Hickey, W. F., Hsu, B. L. and Kimura, H. (1991). T-lymphocyte entry into the central nervous system. J. Neurosci. Res. 28:254-260.
24. Hofman, F. M., Hinton, D. R., Johnson, K. and Merrill, J. E. (1989). Tumor necrosis factor identified in Multiple sclerosis brain. J. Exp. Med. 170:607-612.
25. Jacobs, C. A., Baker, P. E., Roux, E. R., Picha, K. S., Toiuola, B., Waugh, S. and Kennedy, M. K. (1991). Experimental autoimmune encephalomyelitis is exacerbated by IL-1α and suppressed by soluble IL-1 receptor. J. Immunol. 146:2983-2989.
26. Johns, L. D., Flanders, K., C., Ranges, G. E. and Sriram, S. (1991). Successful treatment of experimental encephalomyelitis with transforming growth factor-beta. J. Immunol. 147:1792-1796.
27. Johns, T., Slavin, A. and Bernard, C. (1995). Research directed towards understanding remyelination -an overview. MS Management 2:39-42.
28. Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., Vollmer, T., Weiner, L. P., Wolinsky, J. S., and the Copolymer I MS Study Group. (1995). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting Multiple sclerosis. Neurology 45:1268-1276.
29. Johnson, R. T., Griffin, D. E., Hirsch, R. S., Wolinsky, J. S., Roedenbeck, S., DeSoriano, I. L. and Vaisberg, A. (1984). Measles encephalomyelitis: clinical and immunological studies. N. Engl. J. Med. 310:137-141.
30. Kennedy, M. K., Torrance, D. S., Picha, K. S. and Mohler, K. M. (1992). Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149:2496-2505.
31. Kermode, A. G., Thompson, A. J., Tofts, P., MacManus, D. G., Kendall, B. E., Kingsley, D. P. E., Moseley, I. F., Rudge, P. and McDonald, W. I. (1990). Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in Multiple sclerosis. Brain 113:1477-1489.
32. Kidd, D., Thorpe, J. W., Thompson, A. J., Kendall, B. E., Moseley, I. F., MacManus, D. G., McDonald, W. I. and Miller, D. H. (1993). Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in Multiple sclerosis. Neurology 43:2632-2637.
33. Kort, W. J. (1994). The effect of chronic stress on the immune response. Adv. Neuroimmunol. 4:1-11.
34. Kusnecou, A. V. Grota, L. J., Schmidt, S. G., Bonneau, R. H., Sheridan, J. F., Glaser, R. and Moynihan, J. A. (1992). Decreased herpes simplex viral immunity and enhanced pathogenesis following stressor administration in mice. J. Neuroimmunol. 38:129-138.
35. Li, Fangqin, Linan, M. J., Stein, M. C. and Faustman, D. L. (1995). Reduced expression of peptide-loaded HLA class I molecules on Multiple sclerosis lymphocytes. Ann. Neurol. 38:147-154.
36. Link, J., Soderstrom, M., Olsson, T., Hojeberg, B., Ljungdahl, A. and Link, H. (1994). Increased transforming growth factor-β, interleukin-4, and interferon-δ in Multiple sclerosis. Ann. Neurol. 36:379-386.
37. Lodge, P. A., Allegretta, M., Steinman, L. and Sriram, S. (1994). Myelin basic protein peptide specificity and T cell receptor gene usage of HPRT, mutant T-cell clones in patients with Multiple sclerosis. Ann. Neurol. 36:3734-3740.
38. Martin, R., McFarland, H. F. and McFarlin, D. E. (1992). Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10:153-187.
39. McLaurin, J. and Yong, V. W. (1995). Oligodendrocytes and myelin. Neurol. Clinics 13:23-49.
40. Medaer, R., Stinissen, P., Truyen, L., Raus, J. and Zhang, J. (1995). Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in Multiple sclerosis. Lancet 346:807-808.
41. Miller, D. H., Barkhof, B. E., Berry, I., Kappos, L., Scotti, G, and Thompson, A. J. (1991). Magnetic resonance imaging in monitoring the treatment of Multiple sclerosis: concerted action guidelines. J. Neurol. Neurosurg. Psych. 54:683-688.
42. Minden, S. L., Marder, W. D., Harrold, L. N. and Dor, A. (1993). Multiple sclerosis: A statistical portrait: a compendium of data on demographics, disability, and health service utilization in the United States. Abt Associates, Cambridge, MA.
43. Mosmann, T. R. and Coffman, R. L. (1989). Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv. Immunol. 46:111-147.
44. Nisipeanu, P. and Korczyn, A. D. (1993). Psychological stress as risk factor for exacerbations in Multiple sclerosis. Neurology 43:1311-1312.
45. Owens, T. and Sriram, S. (1995). The immunology of Multiple sclerosis and its animal model, experimental allergic encephalomyelitis. Neurol. Clinics 13:51-73.
46. Panitch, H. S., Hirsch, R. L., Schindler, J. and Johnson, K. P. (1987). Treatment of Multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 37:1097-1102.
47. Panitch, H. S., Katz, E. and Johnson, K. P. (1994). Effects of beta interferon treatment on viral infections and relapses of Multiple sclerosis (abstr.). Neurology 44:A358.
48. Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, IFNβ MS Study Group. (1993). Interferon beta-1b is effective in relapsing-remitting Multiple sclerosis. II. MRI results of a multicenter, randomized double-blind, placebo-controlled trial. Neurology 43:662-667.
49. Paty, D. W., McFarlin, D. E. and McDonald, W. I. (1991). Magnetic resonance imaging and laboratory aids in the diagnosis of Multiple sclerosis. Ann. Neurol. 29:3-5.
50. Peterson, P. K., Chao, C. C., Molitor, T., Murtaugh, M., Strgar, F. and Sharp, B. M. (1991). Stress and pathogenesis of infectious disease. Rev. infect. Dis. 13:710-720.
51. Prineas, J. W., Barnard, R. O., Kwon, E. E., Sharer, L. R. and Cho, E.-S. (1993). Multiple sclerosis: remyelination of nascent lesions. Ann. Neurol. 33:137-151.
52. Prineas, J. W., Kwon, E. E., Goldenberg, P. Z., Ilyas, A. A., Quarles, R. H., Benjamins, J. A. and Sprinkle, T. J. (1989). Multiple sclerosis: oligodendrocyte proliferation and differentiation in fresh lesions. Lab. Invest. 61:489-503.
53. Rackc, M. K., Cannella, B., Albert, P., Sporn, M., Raine, C. S. and McFarlin, D. E. (1992). Evidence of endogenous regulatory function of transforming growth factor β1 in experimental allergic encephalomyelitis. Int. Immunol. 4:615-620.
54. Raine, C. S. (1994). Multiple sclerosis: Immune system molecule expression in the central nervous system. J. Neuropath. Exp. Neurol. 53:328-337.
55. Raine, C. S., Scheinberg, L. C. and Waltz, J. M. (1981). Multiple sclerosis: oligodendrocyte survival and proliferation in an active, established lesion. Lab. Invest. 45:534-546.
56. Raine, C. S. and Wu, E. (1993). Multiple sclerosis: remyelination in acute lesions. J. Neuropathol. Exp. Neurol. 52:199-205.
57. Rieckmann, P., Albrecht, M. Kitze, B., Weber, T., Tumani, H., Broocks, A., Luer, W., Helwig, A. and Poser, S. (1995). Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting Multiple sclerosis is associated with disease activity. Ann. Neurol. 37:82-88.
58. Rodriguez, M. and Lennon, V. A. (1990). Immunoglobulins promote remyelination in the central nervous system. Ann. Neurol. 27:12-17.
59. Rott, O., Cash, E. and Fleischer, B. (1993). Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1-but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomy-elitis in Lewis rats. Eur. J. Immunol. 23:1745-1751.
60. Rozniecki, J. J., Hauser, S. L., Stein, M., Lincoln, R. and Theoharides, T. C. (1995). Elevated mast cell tryptase in cerebrospinal fluid of Multiple sclerosis patients. Ann. Neurol. 37:63-66.
61. Ruddle, N. H., Begman, C. M., McGrath, M., Lingenheld, E. G., Grunnet, M. L., Padula, S. J. and Clark, R. B. (1990). An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1193-1200.
62. Sadovnick, A. D., Baird, P. A. and Ward, R. H. (1988). Multiple sclerosis: updated risks for relatives. Am. J. Med. Genet. 29:533-541.
63. Sadovnick, A. D. and Ebers, G. C. (1995). Genetics of Multiple sclerosis. Neurol. Clin. 13:99-118.
64. Sadovnick, A. D., Rice, G. P. A., Armstrong, H., Bulman, D., Hashimoto, L., Paty, D. W., Hashimoto, S.A., Warren, S., Hader, W., Murray, T. J., Seland, T. P., Metz, L., Bell, R., Duquette, P., Gray, T., Nelson, R., Weinshenker, B., Brunet, D. and Ebers, G. C. (1993). A population-based twin study of Multiple sclerosis in twins: update. Ann. Neurol. 33:281-285.
65. Selmaj, K., Raine, C. S., Cannella, B. and Brosnan, C. F. (1991a). Identification of lymphotoxin and tumor necrosis factor in Multiple sclerosis lesions. J. Clin. Invest. 87:949-954.
66. Selmaj, K., Raine, C. S. and Cross, A. H. (1991b). Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neurol. 30:694-700.
67. Sharief, M. K. and Hentges, R. (1991). Association between tumor necrosis factor-alpha and disease progression in patients with Multiple sclerosis. N. Engl. J. Med. 325:467-472.
68. Sharma, S. D., Bishwajit, N., Su, X.-M., Green, D., Spack, E., Clark, B. R. and Sriram, S. (1991). Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes. Proc. Natl Acad. Sci. 88:11465-11469.
69. Sibley, W. A. (1987). Risk factors in Multiple sclerosis - implications for pathogenesis. In: Serlupi Crescenzi, G. ed. A Multidisciplinary Approach to Myelin Disease, pp. 227-232. Plenum Press, New York.
70. Sibley, W. A., Bamford, C. R. and Clark, K. (1985). Clinical viral infections and Multiple sclerosis. Lancet I:1313-1315.
71. Sobel, R. A. (1995). The pathology of Multiple sclerosis. Neurol. Clinics 13:1-21.
72. Stone, A. A. and Bovbjerg, D. H. (1994). Stress and humoral immunity: a review of the human studies. Adv. Neuroimmunol.4:49-56.
73. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. (1985). Interferon beta-1 in the treatment of Multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277-1285.
74. Toms, R., Weiner, H. L. and Johnson, D. (1990). Identification of IgE-positive cells and mast cells in frozen sections of Multiple sclerosis brains. J. Neuroimmunol. 30:169-177.
75. van Engelen, B. G. M., Hommes, O. R., Pinckers, A., Cruysberg, J. R. M., Barkhof, F. and Rodriguez, M. (1992). Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann. Neurol. 32:834-835.
76. Waksman, B. H. (1995). More genes versus environment. Nature 377:105-106.
77. Wallace, C. J., Seland, T. P. and Fong, T. C. (1992). Multiple sclerosis: The impact of MR imaging. AJR 158:849-857.
78. Warren, K. G., Catz, I., Johnson, E. and Mielke, B. (1994). Anti-myelin basic protein and antiproteolipid protein specific forms of Multiple sclerosis. Ann. Neurol. 35:280-289.
79. Warren, S., Greenhill, S. and Warren, K. G. (1982). Emotional stress and the development of Multiple sclerosis: case-control evidence of a relationship. J. Chronic Dis. 35:821-831.
80. Weiner, H. L., Mackin, G. A., Matsui, M., Orav, E. J., Khoury, S. J., Dawson, D. M. and Hafler, D. A. (1993). Double-blind pilot trial of oral tolerization with myelin antigens in Multiple sclerosis. Science 259:1321-1324.
81. Whitaker, J. N., Kachelhofer, R. D., Bradley, E. L., Burgard, S., Layton, B. A., Reder, A. T., Morrison, W., Zhao, G. J. and Paty, D. W. (1995). Urinary myelin basic protein-like material as a correlate of the progression of Multiple sclerosis. Ann. Neurol. 38:625-632.
82. Wucherpfennig, K. W. and Strominger, J. L. (1995). Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80:695-705.
83. + T cells. Ann. Neurol. 38:723-730.